Lenvatinib plus pembrolizumab in for untreated and previously treated metastatic kidney cancer

Results from a phase Ib/II study looking at lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) showed that there was a response to treatment and the cancer reduced in size (objective response) in 73% of patients who had not received previous medication for their cancer. There were 143 patients in the […]

read more

ASCO 2021: Pembrolizumab plus axitinib continues to improve survival in kidney cancer

The KEYNOTE-426 study of the immune checkpoint inhibitor, pembrolizumab plus the VEGF inhibitor, axitinib for advanced renal cell carcinoma continues to show survival benefits compared with sunitinib as a first treatment after surgery. In this oral presentation from the American Society for Clinical Oncology (ASCO) Annual Meeting, further follow-up data from KEYNOTE-426 over more than […]

read more

ASCO 2021: Health-related quality of life for lenvatinib plus pembrolizumab for advanced kidney cancer

Results from the phase 3 CLEAR study were presented at the American Society for Clinical Oncology (ASCO) Annual Meeting at the weekend. Previous studies have shown that lenvatinib (VEGF inhibitor) used together with pembrolizumab (immune checkpoint inhibitor) resulted in better survival and cancer shrinkage compared to sunitinib when used for patients with advanced renal cell […]

read more

ASCO 2021: Pembrolizumab as adjuvant therapy for kidney cancer

Adjuvant therapy is medication that is given in addition to surgery (nephrectomy) to try to prevent the cancer from coming back. Adjuvant therapy can be used to kill any remaining microscopic cancer cells, or it can control the growth of any remaining cancer. Nephrectomy is the standard of care for renal cell carcinoma (RCC); however, […]

read more

Adjuvant pembrolizumab extends disease-free survival in kidney cancer patients

Interim results from a phase 3 clinical trial called KEYNOTE-564 have shown that pembrolizumab given after nephrectomy (adjuvant pembrolizumab) for intermediate to high risk renal cell carcinoma (RCC) prolonged disease-free survival compared with placebo. Adjuvant pembrolizumab also improved disease-free survival in patients who had surgery to remove metastases. The study included 950 patients with renal […]

read more

Longer term outcomes with pembrolizumab plus axitinib combination for advanced kidney cancer

This Practice Update interview with Dr Monty Pal from City of Hope Hospital, Duarte, USA and Dr Jun Gong from Cidars-Sinai Medical Centre, Los Angeles, USA reports further follow-up data from the KEYNOTE-426 clinical trial. KEYNOTE-426 is a phase 3 trial looking at the effectiveness of a combination of axitinib and pembrolizumab compared to sunitinib […]

read more

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

read more

Pembrolizumab as first-line treatment for kidney cancer

The recent phase II KEYNOTE-427 study investigated the efficacy and safety of pembrolizumab in patients with untreated advanced clear cell renal cell carcinoma (RCC) and non-clear cell RCC. Pembrolizumab is a type of immunotherapy (an immune checkpoint inhibitor called a programmed death 1 inhibitor, PD-1), which has been shown to be effective in untreated patients […]

read more

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC). The pembrolizumab/lenvatinib combination had similar side […]

read more

Pembrolizumab plus axitinib combination accepted by NHS Scotland for first-line treatment of advanced kidney cancer

The¬†Sottish Medicine Consortium (SMC) have issued a final decision to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer. We are delighted that as from today, kidney cancer patients in Scotland can get NHS funding for pemrolizumab in combination with axitinib for untreated patients with advanced or metastatic renal cell […]

read more
Showing 1 to 10 of 52 results
  TOP